The effects of an SPM-enriched marine oil and bioavailable curcumin combination on inflammation-associated discomfort in generally healthy individuals: a virtual open-label pilot study

• Published in: Translational medicine communications Vol. 7; no. 1; pp. 1 - 10
• Main Authors: Jaja-Chimedza, Asha, Hirsh, Steven, Bruce, Dainian, Bou-Sliman, Tony, Joyal, Steven, Swick, Andrew G.
• Format: Journal Article
• Language: English
• Published: London BioMed Central 14.11.2022; BMC
• Subjects: Arthritis; Bioavailability; Biomarkers; Chronic illnesses; Curcumin; Dietary supplements; Fatty acids; Health surveys; Inflammation; Lipids; Neutrophils; Pain; Pain/discomfort; Pro-resolving mediators; Questionnaires; Tumor necrosis factor-TNF
• ISSN: 2396-832X; 2396-832X
• DOI: 10.1186/s41231-022-00131-7

Abstract Background Acute inflammation is the body’s immediate and well-coordinated response to injury, which if not resolved can lead to a state of chronic inflammation and is an important component of aging-associated pathologies and chronic diseases. Resolution of inflammation has been shown to be highly regulated by several endogenous specialized pro-resolving mediators which are metabolized from dietary omega-3 and -6 fatty acids. The aim of this pilot study was to validate the use of a combination of a specialized pro-resolving (SPM) enriched marine oil supplement and a highly bioavailable curcumin supplement to reduce pain/discomfort in healthy adults. Methods This was a virtual (remote), single-arm open-label study in healthy adults with mild to moderate pain. Twenty-nine individuals were provided with an SPM-enriched marine oil supplement (enriched for three SPM precursors) and a highly bioavailable curcumin supplement to be taken daily for 60 days. The Short-Form McGill Pain Questionnaire (SF-MPQ), Short-Form 36 (SF-36) Health Survey and Medical Symptoms Questionnaire (MSQ) were used to evaluate safety, tolerability and efficacy in reducing pain/discomfort of inflammation. Results The SF-MPQ showed significant improvement in all aspects of the questionnaire, especially in total pain, pain intensity and pain severity within 30 days of supplementation. Significant improvements were also observed in the physical health domain of the SF-36 health survey, particularly in the areas of pain and physical functioning at both days 30 and 60. No adverse events related to the study materials were reported during the study. Conclusion In conclusion, the combination of anti-inflammatory and pro-resolving supplements may provide a complementary approach for targeting pain/discomfort associated with inflammation. Trial registration ClinicalTrials.gov , NCT04819646 . Registered 29 March 2021 – Retrospectively registered.